Solitary Pulmonary Nodule

The answer first

A solitary pulmonary nodule is a probability problem wearing a radiology report, and the whole discipline of this topic is converting a circle on a CT into a defensible malignancy probability and then acting on that number [1] [3]. The examiners are not testing whether you can recite a table; they are testing whether you know which framework applies to this patient — because the single commonest error in the DWE is quoting the right guideline for the wrong person [1].

Three working rules carry almost every answer [1] [2]:

1. Find the old imaging before you do anything else. A solid nodule unchanged for two years is effectively benign, and growth on serial imaging overrides every reassuring static feature — the cheapest, highest-yield step in the entire workup costs nothing [1].
2. Stratify risk with a number, not a vibe. Patient factors (age, smoking, emphysema, family history) and nodule factors (size — the dominant variable, spiculation, upper-lobe location, part-solid morphology, growth) combine into a malignancy probability through the Brock or Mayo model, and the probability band chooses surveillance, PET or tissue [2] [3].
3. Subsolid nodules run on a different clock. A persistent part-solid nodule is the highest-risk morphology, its solid component — not its overall diameter — drives management, and its surveillance tail is five years, not two [1] [11].

---

References22Show ledgerHide ledger

1. [1]MacMahon H, Naidich DP, Goo JM, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017 Radiology, 2017.PMID 28240562
2. [2]McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT N Engl J Med, 2013.PMID 24004118
3. [3]Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules Arch Intern Med, 1997.PMID 9129544
4. [4]Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis JAMA, 2001.PMID 11180735
5. [5]Callister ME, Baldwin DR, Akram AR, et al. British Thoracic Society guidelines for the investigation and management of pulmonary nodules Thorax, 2015.PMID 26082159
6. [6]Wiener RS, Schwartz LM, Woloshin S, et al. Population-based risk for complications after transthoracic needle lung biopsy of a pulmonary nodule: an analysis of discharge records Ann Intern Med, 2011.PMID 21810706
7. [7]Heerink WJ, de Bock GH, de Jonge GJ, et al. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis Eur Radiol, 2017.PMID 27108299
8. [8]Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic Navigation Bronchoscopy for Peripheral Pulmonary Lesions: One-Year Results of the Prospective, Multicenter NAVIGATE Study J Thorac Oncol, 2019.PMID 30476574
9. [9]Steinfort DP, Khor YH, Manser RL, et al. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis Eur Respir J, 2011.PMID 20693253
10. [10]Pinsky PF, Gierada DS, Black W, et al. Performance of Lung-RADS in the National Lung Screening Trial: a retrospective assessment Ann Intern Med, 2015.PMID 25664444
11. [11]Henschke CI, Yankelevitz DF, Mirtcheva R, et al. CT screening for lung cancer: frequency and significance of part-solid and nonsolid nodules AJR Am J Roentgenol, 2002.PMID 11959700
12. [12]Hasegawa M, Sone S, Takashima S, et al. Growth rate of small lung cancers detected on mass CT screening Br J Radiol, 2000.PMID 11205667
13. [13]Saji H, Okada M, Tsuboi M, et al. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial Lancet, 2022.PMID 35461558
14. [14]Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening Lancet Oncol, 2014.PMID 25282285
15. [15]Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography Chest, 2005.PMID 16236914
16. [16]Silvestri GA, Tanner NT, Kearney P, et al. Assessment of Plasma Proteomics Biomarker's Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial Chest, 2018.PMID 29496499
17. [17]Ardila D, Kiraly AP, Bharadwaj S, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography Nat Med, 2019.PMID 31110349
18. [18]Khouri NF, Meziane MA, Zerhouni EA, et al. The solitary pulmonary nodule. Assessment, diagnosis, and management Chest, 1987.PMID 3792065
19. [19]Kakinuma R, Ohmatsu H, Kaneko M, et al. Progression of focal pure ground-glass opacity detected by low-dose helical computed tomography screening for lung cancer J Comput Assist Tomogr, 2004.PMID 14716227
20. [20]Krist AH, Davidson KW, Mangione CM, et al. Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement JAMA, 2021.PMID 33687470
21. [21]de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial N Engl J Med, 2020.PMID 31995683
22. [22]Aberle DR, Adams AM, Berg CD, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening N Engl J Med, 2011.PMID 21714641